Literature DB >> 31309327

Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey.

Yoshitaka Murakami1, Yuji Nishiwaki2, Mari S Oba3, Keiko Asakura2, Satoko Ohfuji4, Wakaba Fukushima4, Yasuo Suzuki5, Yosikazu Nakamura6.   

Abstract

BACKGROUND: Almost a quarter century has passed since the first nationwide survey on ulcerative colitis (UC) and Crohn's disease (CD) was conducted in Japan. In this study, we used a nationwide survey to estimate the number of patients and prevalence of these diseases in Japan in 2014.
METHODS: We conducted a mail-based survey targeting hospitals to estimate the annual numbers of patients with UC and CD in 2014. Respondents were asked to report the numbers of patients who met specific diagnostic criteria for these two conditions. A stratified random sampling method was used, and a total of 3712 departments (internal medicine, surgery, pediatrics, and pediatric surgery) were selected for analysis. The overall and sex-specific annual numbers of UC and CD patients were estimated. The corresponding prevalence rates per 100,000 population were calculated by dividing the number of patients with each disease by the mid-year population of Japan in 2014.
RESULTS: The overall survey response rate was 56.7% (2016 departments). The estimated numbers of patients with UC and CD were 219,685 (95% confidence interval: 183,968-255,403) and 70,700 (56,702-84,699), respectively. The annual prevalence rates of UC and CD per 100,000 population were 172.9 (men: 192.3; women: 154.5) and 55.6 (men: 79.5; women: 33.1), respectively. These numbers are almost tenfold increase in comparing the previous survey (22,300 in UC and 7,400 in CD). The male-to-female ratios were 1.24 for UC and 2.40 for CD, and the UC-to-CD ratio was 3.11.
CONCLUSIONS: The prevalence of UC and CD in Japan has risen substantially over the past two decades, and their disease burden requires further examination.

Entities:  

Keywords:  Crohn’s disease; Epidemiology; Nationwide survey; Prevalence; Ulcerative colitis

Year:  2019        PMID: 31309327     DOI: 10.1007/s00535-019-01603-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  17 in total

1.  Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan.

Authors:  Y Nakamura; T Matsumoto; A Tamakoshi; T Kawamura; Y Seino; M Kasuga; H Yanagawa; Y Ohno
Journal:  J Epidemiol       Date:  2000-01       Impact factor: 3.211

Review 2.  Progression of inflammatory bowel disease in China.

Authors:  Yu Fang Wang; Qin Ouyang; Ren Wei Hu
Journal:  J Dig Dis       Date:  2010-04       Impact factor: 2.325

3.  [A method of interval estimation for number of patients in the nationwide epidemiological survey on intractable diseases].

Authors:  S Hashimoto; K Fukutomi; M Nagai; Y Nakamura; H Yanagawa; R Sasaki; Y Ohno; N Kubo; K Aoki
Journal:  Nihon Koshu Eisei Zasshi       Date:  1991-11

4.  Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991.

Authors:  N Morita; S Toki; T Hirohashi; T Minoda; K Ogawa; S Kono; A Tamakoshi; Y Ohno; T Sawada; T Muto
Journal:  J Gastroenterol       Date:  1995-11       Impact factor: 7.527

5.  Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists.

Authors:  B Moum; M H Vatn; A Ekbom; O Fausa; E Aadland; I Lygren; J Sauar; T Schulz
Journal:  Digestion       Date:  1995       Impact factor: 3.216

6.  Smoking and inflammatory bowel disease: a meta-analysis.

Authors:  Suhal S Mahid; Kyle S Minor; Roberto E Soto; Carlton A Hornung; Susan Galandiuk
Journal:  Mayo Clin Proc       Date:  2006-11       Impact factor: 7.616

7.  Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study.

Authors:  Siew C Ng; Whitney Tang; Jessica Y Ching; May Wong; Chung Mo Chow; A J Hui; T C Wong; Vincent K Leung; Steve W Tsang; Hon Ho Yu; Mo Fong Li; Ka Kei Ng; Michael A Kamm; Corrie Studd; Sally Bell; Rupert Leong; H Janaka de Silva; Anuradhani Kasturiratne; M N F Mufeena; Khoon Lin Ling; Choon Jin Ooi; Poh Seng Tan; David Ong; Khean L Goh; Ida Hilmi; Pises Pisespongsa; Sathaporn Manatsathit; Rungsun Rerknimitr; Satimai Aniwan; Yu Fang Wang; Qin Ouyang; Zhirong Zeng; Zhenhua Zhu; Min Hu Chen; Pin Jin Hu; Kaichun Wu; Xin Wang; Marcellus Simadibrata; Murdani Abdullah; Justin Cy Wu; Joseph J Y Sung; Francis K L Chan
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

8.  Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head.

Authors:  Wakaba Fukushima; Mikihiro Fujioka; Toshikazu Kubo; Akiko Tamakoshi; Masaki Nagai; Yoshio Hirota
Journal:  Clin Orthop Relat Res       Date:  2010-03-12       Impact factor: 4.176

9.  Prevalence of ulcerative colitis and Crohn's disease in Japan.

Authors:  Keiko Asakura; Yuji Nishiwaki; Nagamu Inoue; Toshifumi Hibi; Mamoru Watanabe; Toru Takebayashi
Journal:  J Gastroenterol       Date:  2009-05-08       Impact factor: 7.527

10.  Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study.

Authors:  Suk-Kyun Yang; Sungcheol Yun; Jin-Ho Kim; Joon Yong Park; Hak Yang Kim; Young-Ho Kim; Dong Kyung Chang; Joo Sung Kim; In Sung Song; Jong Beom Park; Eui-Ryun Park; Kyung Jo Kim; Gyoo Moon; Soo Hyun Yang
Journal:  Inflamm Bowel Dis       Date:  2008-04       Impact factor: 5.325

View more
  28 in total

1.  Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use.

Authors:  Danielle Bargo; Theo Tritton; Joseph C Cappelleri; Marco DiBonaventura; Timothy W Smith; Takanori Tsuchiya; Sean Gardiner; Irene Modesto; Tim Holbrook; Daniel Bluff; Taku Kobayashi
Journal:  Inflamm Intest Dis       Date:  2021-11-17

2.  Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).

Authors:  Katsuyoshi Matsuoka; Toshimitsu Fujii; Ryuichi Okamoto; Akihiro Yamada; Reiko Kunisaki; Minoru Matsuura; Kenji Watanabe; Hisashi Shiga; Noritaka Takatsu; Shigeki Bamba; Yohei Mikami; Takayuki Yamamoto; Takahiro Shimoyama; Satoshi Motoya; Takehiro Torisu; Taku Kobayashi; Naoki Ohmiya; Masayuki Saruta; Koichiro Matsuda; Takayuki Matsumoto; Hiroshi Nakase; Atsuo Maemoto; Shinichiro Shinzaki; Yoko Murata; Shinichi Yoshigoe; Ayako Sasaki; Tsutomu Yajima; Tadakazu Hisamatsu
Journal:  J Gastroenterol       Date:  2022-08-05       Impact factor: 6.772

3.  Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.

Authors:  Jiali Wang; Fushun Kou; Xiao Han; Lei Shi; Rui Shi; Zhibin Wang; Tangyou Mao; Junxiang Li
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

4.  Does the road to primary prevention of inflammatory bowel disease start from childhood?

Authors:  Saurabh Kedia; Vineet Ahuja
Journal:  JGH Open       Date:  2022-06-22

5.  Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.

Authors:  Shinichiro Shinzaki; Katsuyoshi Matsuoka; Hiroki Tanaka; Fuminao Takeshima; Shingo Kato; Takehiro Torisu; Yuki Ohta; Kenji Watanabe; Shiro Nakamura; Naoki Yoshimura; Taku Kobayashi; Akiko Shiotani; Fumihito Hirai; Sakiko Hiraoka; Mamoru Watanabe; Minoru Matsuura; Shohei Nishimoto; Shinta Mizuno; Hideki Iijima; Tetsuo Takehara; Tetsuji Naka; Takanori Kanai; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2021-05-03       Impact factor: 7.527

Review 6.  Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.

Authors:  Hiroshi Nakase; Motoi Uchino; Shinichiro Shinzaki; Minoru Matsuura; Katsuyoshi Matsuoka; Taku Kobayashi; Masayuki Saruta; Fumihito Hirai; Keisuke Hata; Sakiko Hiraoka; Motohiro Esaki; Ken Sugimoto; Toshimitsu Fuji; Kenji Watanabe; Shiro Nakamura; Nagamu Inoue; Toshiyuki Itoh; Makoto Naganuma; Tadakazu Hisamatsu; Mamoru Watanabe; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-04-22       Impact factor: 7.527

7.  Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.

Authors:  Celine Miyazaki; Nagano Katsumasa; Kuan Chih Huang; Yan Fang Liu
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

8.  Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016.

Authors:  Katsuyoshi Matsuoka; Ataru Igarashi; Noriko Sato; Yuri Isono; Maki Gouda; Katsuhiko Iwasaki; Ayako Shoji; Tadakazu Hisamatsu
Journal:  J Crohns Colitis       Date:  2020-08-26       Impact factor: 9.071

9.  Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis.

Authors:  Katsuyoshi Matsuoka; Hirono Ishikawa; Takeo Nakayama; Yusuke Honzawa; Atsuo Maemoto; Fumihito Hirai; Fumiaki Ueno; Noriko Sato; Yutaka Susuta; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2021-07-27       Impact factor: 7.527

10.  Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan.

Authors:  Seiji Yokoyama; Teita Asano; Katsumasa Nagano; Hiroaki Tsuchiya; Masayuki Takagishi; Shigeharu Tsujioka; Naomi Miura; Takayuki Matsumoto
Journal:  J Gastroenterol Hepatol       Date:  2021-07-22       Impact factor: 4.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.